Yann Bordat

TL;DR: A novel strategy to engineer immunocytokines with very high targeting efficacies is presented, using mutants of toxic cytokines that markedly reduce their receptor-binding affinities, and that are thus rendered essentially inactive.

TL;DR: In comparison to similar quaternary ammonium salts, amidinium compounds have distinct structural requirements for antimalarial activity and likely additional binding opportunities on account of their hydrogen-bond-forming properties.

TL;DR: A new dense granule protein that should now be referred to as GRA12, and that displays no homology with other proteins is described, that exists in both a soluble and a membrane-associated form within the vacuolar space.

TL;DR: AcTakines (Activity-on-Target cytokines), optimized (mutated) immunocytokines that are up to 1,000-fold more potent on target cells, allowing specific signaling in selected cell types only are developed, indicating that DC-targeted AFNs provide a novel class of highly efficient, safe, and broad-spectrum off-the-shelf cancer immunotherapeutics with no need for a tumor marker.

TL;DR: Albitiazolium, which is currently in phase II clinical trials to cure severe malaria, is dissected step by step from choline entry into the infected erythrocyte to its effect on phosphatidylcholine biosynthesis.